Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I2DV
|
|||
| Drug Name |
1-phenyl-1,3,4-triazole derivative 3
|
|||
| Synonyms |
PMID28454500-Compound-78
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
THE GENERAL HOSPITAL CORPORATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H15N5O2S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C2=NN=C(N2C3=CC=CC=C3)SC4=C5C(=C(C=C4)[N+](=O)[O-])C=CC=N5
|
|||
| InChI |
1S/C23H15N5O2S/c29-28(30)19-13-14-20(21-18(19)12-7-15-24-21)31-23-26-25-22(16-8-3-1-4-9-16)27(23)17-10-5-2-6-11-17/h1-15H
|
|||
| InChIKey |
RAPJMMAHETVTFD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 87236-38-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) | Target Info | Modulator | [1] |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) | Target's Patent Info | [1] | |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.